A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled

A Phase 1, Open-label, Randomised, Crossover Study to Determine the Comparative Bioavailability of 20 mg Lomitapide Where the Contents Have Been Opened and Sprinkled in Applesauce or Mashed Banana ("Sprinkled Contents") to a Single Oral Capsule Dose of 20 mg Lomitapide ("Intact Capsule") in Healthy Subjects

To compare the relative bioavailability of lomitapide when administered by sprinkling the contents of a 20 mg capsule of lomitapide in applesauce or in mashed banana to a single oral intact capsule dose of 20 mg lomitapide in healthy subjects.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: lomitapide

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Surrey
    • Croydon, Surrey, United Kingdom, CR7 7YE
      • Richmond Pharmacology Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject is a non-smoking healthy male or female, aged between 18 and 40 years of age.
2. Subject has a BMI of 18.5 - 25 kg/m2.
3. Subject has total body weight between > 50 kg to ≤ 100 kg.
4. Subjects must agree to use acceptable methods of contraception.
5. All females, regardless of childbearing potential, must have a negative serum beta human chorionic gonadotropin pregnancy test at Screening and on admission.
6. In good health, determined by no clinically significant or relevant abnormalities identified by a detailed medical history & full physical examination.
7. No known history of hypersensitivity or previous intolerance to lomitapide, applesauce, and/or banana.
8. Subjects must be capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form prior to undergoing any study-related procedures.

Exclusion Criteria:

1. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion.
2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
3. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations.
4. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator;
5. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) such as a QTcF interval of >450 msec, a history of a prolonged QTc interval or Brugada syndrome.
6. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, allergic, dermatological, metabolic, neurological, psychiatric or other disease.
7. History or laboratory evidence of Gilbert's syndrome.
8. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg), anti-Hepatitis core antibody (anti-HBc Ig G [and anti-HBc IgM if IgG is positive], Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2).
9. Use of any drugs of abuse within 6 months prior to admission.
10. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates and methadone) or from the alcohol breath test at screening and on admission (Day -1).
11. History or clinical evidence of alcohol or drug abuse within one year prior to admission.
12. Mentally handicapped.
13. Participation in a drug trial within 90 days prior to first drug administration.
14. Use of any prescription medication within 2 weeks prior to admission (Day -1), with the exception of the oral contraceptive pill.
15. Use of any substance inducing or inhibiting CYP3A4 enzymes within 30 days prior to admission (Day -1).
16. Use of any over-the-counter (OTC) medication (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to admission (Day -1), unless deemed acceptable by the Investigator and Sponsor.
17. Use of alcohol-, grapefruit-, starfruit-, or caffeine-containing foods or beverages within 72 hours prior to admission and through Study Completion.
18. Donation of more than 500 mL of blood within 90 days prior to drug administration.
19. Receipt of blood products within 2 months prior to admission.
20. Poor peripheral venous access.
21. Use of any tobacco- or nicotine-containing products within 6 months prior to admission (Day -1).
22. Any acute or chronic condition, scheduled hospitalisation (inclusive of elective surgery during study), or scheduled travel prior to completion of all study procedures.
23. Any circumstances or conditions, which, in the opinion of the PI, may affect full participation in the trial or compliance with the protocol.
24. Legal incapacity or limited legal capacity at screening.
25. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with the study standardised menus.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: lomitapide sprinkled in applesauce; Contents of single 20 mg capsule of lomitapide sprinkled in applesauce	Drug: lomitapide; Other Names: Juxtapid; Lojuxta
Experimental: lomitapide sprinkled in mashed banana; Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana	Drug: lomitapide; Other Names: Juxtapid; Lojuxta
Experimental: lomitapide (intact); Intact capsule of 20 mg lomitapide	Drug: lomitapide; Other Names: Juxtapid; Lojuxta

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-t	Area under the concentration-time curve from hour 0 to the last measurable concentration of lomitapide and its metabolites (M1& M3).	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Cmax	Maximum observed concentration of lomitapide and its metabolites (M1& M3).	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Tmax	Time to reach maximum plasma concentration of lomitapide and its metabolites (M1& M3).	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
t1/2	Terminal elimination half-life of lomitapide and its metabolites (M1& M3).	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
AUC0-∞	Area under the plasma concentration vs time curve from zero to infinity of lomitapide and its metabolites (M1& M3).	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
λz	Elimination rate constant estimated from individual linear regression of the terminal part of the log concentration vs time curve of lomitapide and its metabolites (M1& M3).	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

Collaborators and Investigators

• Sponsor: Aegerion Pharmaceuticals, Inc.
• Investigators: Study Chair: Mark Sumeray, MD, Aegerion Pharmaceuticals, Inc.; Principal Investigator: Ulrike Lorch, MD, Richmond Phamacology, LTD

Study record dates

Study Major Dates

• Study Start (Actual): October 30, 2013
• Primary Completion (Actual): December 23, 2013
• Study Completion (Actual): December 23, 2013

Study Registration Dates

• First Submitted: November 6, 2013
• First Submitted That Met QC Criteria: January 22, 2014
• First Posted (Estimate): January 24, 2014

Study Record Updates

• Last Update Posted (Actual): February 13, 2018
• Last Update Submitted That Met QC Criteria: February 8, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Keywords: Bioavailability; lomitapide; Comparative
• Other Study ID Numbers: AEGR-733-032